NDAORALCAPSULE, TABLET, TABLETPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA TRIPLE PAK is a fixed-dose combination of vonoprazan fumarate (a potassium-competitive acid blocker), amoxicillin, and clarithromycin for oral administration. It is indicated for Helicobacter pylori eradication in patients with peptic ulcer disease or gastric MALT lymphoma. The combination leverages vonoprazan's enhanced acid suppression to optimize antibiotic efficacy.
Peak3.8 years to LOE
Product is in peak commercial phase post-2022 launch; commercial team likely stable or growing as market penetration expands against established H. pylori regimens.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on VOQUEZNA TRIPLE PAK at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.